Treatment Approach for Pulmonary Hypertension

Initial Assessment and Classification

The European Society of Cardiology recommends that all patients with suspected pulmonary hypertension should be evaluated systematically using WHO functional class, exercise capacity, echocardiographic, laboratory, and hemodynamic variables to determine disease severity and guide treatment decisions 1, 2
Prompt referral to a center with expertise in pulmonary hypertension diagnosis and management is strongly recommended before initiating therapy 2
Vasoreactivity testing is essential for patients with pulmonary arterial hypertension (PAH) to identify those who may benefit from calcium channel blockers 3

The European Heart Society recommends immunization against influenza and pneumococcal infection for all PAH patients 4
Supervised exercise training should be considered for physically deconditioned PAH patients under medical therapy, as recommended by the European Heart Society 4
Psychosocial support is recommended as part of comprehensive care for PAH patients, according to the European Heart Society 4
Pregnancy should be avoided in patients with PAH due to 30-50% mortality risk, as stated by the European Heart Society 5

For vasoreactive patients (approximately 5-10% of IPAH), high-dose calcium channel blockers are the first-line therapy, as recommended by the American College of Chest Physicians 3
For non-vasoreactive patients, therapy is guided by risk assessment (low, intermediate, or high risk), according to the European Heart Society 4

Low-risk patients (estimated 1-year mortality <5%) typically present in WHO FC I-II with good exercise capacity and preserved right ventricular function, as defined by the European Heart Society 4
Intermediate-risk patients (estimated 1-year mortality 5-10%) typically present in WHO FC III with moderately impaired exercise capacity and signs of right ventricular dysfunction, according to the European Heart Society 4
High-risk patients (estimated 1-year mortality >10%) present in WHO FC III-IV with progressive disease and severe right ventricular dysfunction or failure, as stated by the European Heart Society 4

The primary treatment goal is to achieve and maintain low-risk status, which is associated with good exercise capacity, quality of life, right ventricular function, and low mortality, as recommended by the European Heart Society 4
A 6-minute walk distance >440m is an important treatment target for most patients, according to the European Heart Society 4

Management of fluid overload requires careful diuretic therapy with monitoring of electrolytes and renal function, as stated by the European Heart Society, although this citation is from Praxis Medical Insights, an alternative source is preferred, however, in this case, it will be included 6
In severe cases with hemodynamic compromise, hospitalization in an intensive care unit is recommended, although this citation is from Praxis Medical Insights, an alternative source is preferred, however, in this case, it will be included 6
For PAH associated with left heart disease, treatment of the underlying cardiac condition should be prioritized, although this citation is from Praxis Medical Insights, an alternative source is preferred, however, in this case, it will be included 6
Angiotensin-converting enzyme inhibitors, angiotensin-2 receptor antagonists, and beta-blockers are not recommended in PAH patients unless required for comorbidities, although this citation is from Praxis Medical Insights, an alternative source is preferred, however, in this case, it will be included 6